Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0K5NZ
|
||||
| Former ID |
DNC005817
|
||||
| Drug Name |
MESULERGINE
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C18H26N4O2S
|
||||
| InChI |
InChI=1S/C18H26N4O2S/c1-20(2)25(23,24)19-13-9-15-14-6-5-7-16-18(14)12(10-21(16)3)8-17(15)22(4)11-13/h5-7,10,13,15,17,19H,8-9,11H2,1-4H3/t13-,15+,17+/m0/s1
|
||||
| InChIKey |
JLVHTNZNKOSCNB-YSVLISHTSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
8192388, 14754853, 26756534, 43125362, 47957327, 48032592, 50048639, 57317105, 75357719, 85787468, 92308808, 92729791, 103934495, 104343219, 117631071, 124892408, 135028814, 135650580, 135928323, 137147715, 140438701, 142950047, 144205576, 160677128, 162222589, 162634974, 163425775, 170466174, 176484040, 198945608, 224639407, 226635052
|
||||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine 7 receptor | Target Info | Inhibitor | [2] | |
| 5-hydroxy-tryptamine 3B receptor | Target Info | Inhibitor | [3] | ||
| Adenosine A3 receptor | Target Info | Inhibitor | [4] | ||
| 5-hydroxytryptamine receptor 3A | Target Info | Inhibitor | [3] | ||
| KEGG Pathway | Ras signaling pathway | ||||
| Calcium signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Serotonergic synapsehsa04726:Serotonergic synapsehsa04726:Serotonergic synapse | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathwayP04375:5HT3 type receptor mediated signaling pathwayP04375:5HT3 type receptor mediated signaling pathway | ||||
| PathWhiz Pathway | Excitatory Neural Signalling Through 5-HTR 7 and Serotonin | ||||
| Reactome | Serotonin receptors | ||||
| G alpha (s) signalling eventsR-HSA-975298:Ligand-gated ion channel transportR-HSA-417973:Adenosine P1 receptors | |||||
| G alpha (i) signalling eventsR-HSA-975298:Ligand-gated ion channel transport | |||||
| WikiPathways | Serotonin Receptor 4/6/7 and NR3C Signaling | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, OtherWP2670:Iron uptake and transportWP80:Nucleotide GPCRs | |||||
| GPCRs, OtherWP706:SIDS Susceptibility Pathways | |||||
| Iron uptake and transport | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 206). | ||||
| REF 2 | J Med Chem. 2009 Apr 23;52(8):2384-92.Synthesis of new serotonin 5-HT7 receptor ligands. Determinants of 5-HT7/5-HT1A receptor selectivity. | ||||
| REF 3 | J Med Chem. 1997 Oct 24;40(22):3670-8.Novel and highly potent 5-HT3 receptor agonists based on a pyrroloquinoxaline structure. | ||||
| REF 4 | J Med Chem. 2005 Nov 3;48(22):6887-96.2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.